{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:49:09Z","timestamp":1786992549791,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jhep.2024.06.031","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T06:18:34Z","timestamp":1720937914000},"page":"28-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide"],"prefix":"10.1016","volume":"82","author":[{"given":"Maria","family":"Buti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-4870","authenticated-orcid":false,"given":"Soo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Chulanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viacheslav","family":"Morozov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3814-7342","authenticated-orcid":false,"given":"Olga","family":"Sagalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-3189","authenticated-orcid":false,"given":"Robert G.","family":"Gish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita M.","family":"Kaushik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vithika","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3873-096X","authenticated-orcid":false,"given":"Dmitry","family":"Manuilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu O.","family":"Osinusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.06.031_bib1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3390\/v14081749","article-title":"A\u00a0review of HDV infection","volume":"14","author":"Caviglia","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2024.06.031_bib2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/infdis\/141.5.590","article-title":"Transmission of the hepatitis B virus-associated delta antigen to chimpanzees","volume":"141","author":"Rizzetto","year":"1980","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2024.06.031_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.06.031_bib4","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2024.06.031_bib5","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.3748\/wjg.v25.i32.4580","article-title":"Chronic hepatitis delta: a state-of-the-art review and new therapies","volume":"25","author":"Gilman","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2024.06.031_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","article-title":"Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead","volume":"7","author":"Wedemeyer","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.06.031_bib7","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/jgh.12217","article-title":"Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California","volume":"28","author":"Gish","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.06.031_bib8","article-title":"Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B","volume":"3","author":"Buti","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.06.031_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.06.031_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.06.031_bib11","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.06.031_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.06.031_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.06.031_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2024.06.031_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.15410","article-title":"Interferon-based treatment of chronic hepatitis D","volume":"43","author":"Sandmann","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.06.031_bib16","article-title":"Summary of product characteristics","year":"2023","journal-title":"Gilead Sciences Ireland UC, County Cork. Ireland"},{"key":"10.1016\/j.jhep.2024.06.031_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A\u00a0phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.06.031_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/A:1008884805251","article-title":"A\u00a0questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C","volume":"7","author":"Bayliss","year":"1998","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhep.2024.06.031_bib19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jhep.2024.06.031_bib20","series-title":"EQ-5D-3L user guide","year":"2018"},{"key":"10.1016\/j.jhep.2024.06.031_bib21","doi-asserted-by":"crossref","DOI":"10.5888\/pcd17.200324","article-title":"Needs of individuals living with hepatitis delta virus and their caregivers, 2016-2019","volume":"17","author":"Kumar","year":"2020","journal-title":"Prev Chronic Dis"},{"key":"10.1016\/j.jhep.2024.06.031_bib22","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s10620-015-4006-0","article-title":"Fatigue in patients with chronic hepatitis B living in North America: results from the Hepatitis B Research Network (HBRN)","volume":"61","author":"Evon","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2024.06.031_bib23","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/liv.15602","article-title":"Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: an analysis of the HIDIT-II trial","volume":"43","author":"Dinkelborg","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.06.031_bib24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1477-7525-11-82","article-title":"Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study","volume":"11","author":"Strand","year":"2013","journal-title":"Health Qual Life Outcomes"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824023377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824023377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:59:59Z","timestamp":1773457199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824023377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0168827824023377"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.06.031","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}